The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.
Anthony M. Joshua
Consultant or Advisory Role - Astellas Pharma (U)
Neal D. Shore
Consultant or Advisory Role - Astellas Pharma; Medivation
Fred Saad
Consultant or Advisory Role - Astellas Pharma; Medivation
Honoraria - Astellas Pharma
Research Funding - Astellas Pharma; Medivation
Kim N. Chi
Consultant or Advisory Role - Astellas Pharma
Honoraria - Astellas Pharma
Carl A. Olsson
Consultant or Advisory Role - Medivation
Honoraria - Medivation
Research Funding - Astellas Pharma
Other Remuneration - Medivation
Urban Emmenegger
Consultant or Advisory Role - Astellas Pharma
Honoraria - Astellas Pharma
Research Funding - Astellas Pharma
Mark C. Scholz
No relevant relationships to disclose
William R. Berry
No relevant relationships to disclose
Som Mukherjee
Honoraria - Amgen; Astellas Pharma; Janssen
Eric Winquist
No relevant relationships to disclose
Naomi B. Haas
No relevant relationships to disclose
Nahla Hasabou
Employment or Leadership Position - Astellas Pharma
Carl Dmuchowski
Employment or Leadership Position - Astellas Pharma
Frank Perabo
Employment or Leadership Position - Astellas Pharma
Mohammad Hirmand
Employment or Leadership Position - Medivation
Margaret A. Foley
Employment or Leadership Position - Astellas Pharma
Dana E. Rathkopf
Research Funding - Astellas Pharma; Medivation